Over expression of HER2 seen in some cases of breast cancer is an indicator of poor prognosis for these patients.5 Since 2000, HER2 test has been approved by FDA and is used in the management and follow-up of patients with metastatic breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.